ClinicalTrials.gg
CompletedNCT07517627ED-LCUpdated Oct 7, 2026

Optimal Timings of Laparoscopic Cholecystectomy After ERCP in Patients With Gallstones Along With CBD Stones

An interventional study of Early laparoscopic cholecystectomy and Delayed Laparoscopic cholecystectomy in Cholelithiasis Associated With Common Bile Duct Stones, sponsored by Rija Zainab. Completed at 1 site in Pakistan. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Rija Zainab · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2025, registered Sep 2025).
Updated Oct 7, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
14 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Cholelithiasis with a site in Pakistan — 2 open to participants now, 2 under way, none of them phase 3. Cholelithiasis · Pakistan.

Enrollment
12th of 12
40 · median 80
Started
2025
with 2 others
No phase
10 of 12
2 open now
Registered
6th of 12
by date

Among the 12 studies in Cholelithiasis with a site in Pakistan, this one is the 12th largest by enrollment, is one of 3 that started in 2025, is one of 10 with no phase, and was the 6th registered.

Cholelithiasis

192 studies on the registry are indexed under Cholelithiasis; 44 are open to participants now.

Browse Cholelithiasis studies →

Open to participants now

2 of the 12 studies in Cholelithiasis with a site in Pakistan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 30 Cholelithiasis studies recruiting now, 20 (67%) set no upper age limit and 7 (23%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 14 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Cholelithiasis with a site in Pakistan, or all of them as a file.
02

Study summary

This randomized controlled trial aims to compare the mean operative time and outcomes of early versus delayed laparoscopic cholecystectomy after ERCP in patients with cholelithiasis and choledocholithiasis. Patients will be randomized into two groups: early cholecystectomy (within 72 hours of ERCP) and delayed cholecystectomy (≥1 month after ERCP). Outcomes include operative time, intra-operative blood loss, hospital stay, and conversion to open cholecystectomy

Read the detailed description

Gallstones are among the most common surgical problems worldwide, and up to 20% of patients with gallstones also present with stones in the common bile duct. Standard care involves clearance of bile duct stones, typically by Endoscopic Retrograde Cholangiopancreaticography (ERCP), followed by removal of the gallbladder by laparoscopic cholecystectomy (LC).

The timing of cholecystectomy after ERCP remains debated. Early LC (within 72 hours) has been associated with fewer recurrent biliary events, reduced hospital stay, and potentially easier operative conditions. However, delayed LC (after one month) continues to be widely practiced due to institutional factors and scheduling constraints.

This randomized controlled trial at Sheikh Zayed Hospital, Lahore, is designed to evaluate whether early LC after ERCP offers measurable advantages compared with delayed LC. Patients with confirmed cholelithiasis and choledocholithiasis will be randomized into two groups: early surgery and delayed surgery. The trial will provide local evidence to guide surgical practice, focusing on operative efficiency and patient recovery.

By clarifying the optimal timing of LC after ERCP in our patient population, the study aims to support evidence-based surgical decision-making, improve outcomes, and potentially reduce healthcare costs.

03

Conditions studied

  • Cholelithiasis Associated With Common Bile Duct Stones

Browse trials for

04

Who can participate

Ages eligible
14 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with cholelithiasis with choledocholithiasis based on clinical and radiological findings (right subcostal pain, presence of gallstones, and dilated common bile duct on ultrasound and MRCP)
  • Age 14 to 70 years
  • Both males and females
  • Duration of symptoms less than 3 days
  • Presence of common bile duct stone with successful clearance on ERCP

Exclusion criteria

Exclusion Criteria

  • Features suggestive of on imaging
  • Patients who develop severe pancreatitis after ERCP
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Early laparoscopic cholecystectomy

    Patients will undergo laparoscopic cholecystectomy within 72hours followed by successful ERCP

    Procedure: Early laparoscopic cholecystectomy

  • Active comparator
    Delayed Laparoscopic cholecystectomy

    Patients will undergo laparoscopic cholecystectomy 4 weeks or more after successful ERCP

    Procedure: Delayed Laparoscopic cholecystectomy

Interventions

  • ProcedureEarly laparoscopic cholecystectomy

    Laparoscopic removal of gall bladder within 72hours of laparoscopic cholecystectomy

  • ProcedureDelayed Laparoscopic cholecystectomy

    Laparoscopic removal of gall bladder 4 weeks or more after successful ERCP

06

What researchers measure

Primary outcomes

  1. Mean Operative time

    Duration of surgery measured from the first incision to closure of the last incision.

    Time frame: During surgery

Secondary outcomes

  1. Length of Hospital Stay

    Total number of days from hospital admission to discharge.

    Time frame: From admission to discharge (up to 30 days)

  2. Intraoperative Blood Loss

    Blood loss measured in milliliters from suction apparatus during surgery.

    Time frame: During Surgery

  3. Conversion to Open Cholecystectomy

    Number of patients requiring conversion from laparoscopic to open surgery

    Time frame: During Surgery

07

Study locations

1 site
  • Shaikh Zayed hospital Lahore
    Lahore, Punjab Province 54000, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because there is no plan to make individual participant-level data available to other researchers. Only aggregate study results will be reported.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Oct 2025, 5 months.

Of 54 non-industry interventional studies with no phase under Cholelithiasis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's 5 months is below that.

Counting every sponsor, half of 58 studies reached it within 15 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Oct 2026 → Oct 2025 and completion Oct 2026 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2025
First posted
Apr 8, 2026
StartActual
May 5, 2025
Primary completionActual
Oct 6, 2025was Oct 2026
CompletionActual
Feb 1, 2026was Oct 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 7, 2026
Primary completion
Oct 2026→Oct 6, 2025 (actual)
Oct 7, 2026
Study completion
Oct 2026→Feb 1, 2026 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Recruiting→Completed
    Primary completion Oct 2026→Oct 6, 2025 (now actual)
    Study completion Oct 2026→Feb 1, 2026 (now actual)
    + 5 other changes: verification date, arm descriptions, contact details, site details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07517627
Lead sponsor
Rija Zainab
Collaborators
Shaikh Zayed Hospital, Lahore
Responsible party
Rija Zainab (Postgraduate Resident, Department of General Surgery, Sheikh Zayed Hospital, Lahore, Shaikh Zayed Hospital, Lahore) — Sponsor-investigator
First posted
Apr 8, 2026
Start date
May 5, 2025
Primary completion
Oct 6, 2025
Completion
Feb 1, 2026
Last update
Oct 7, 2026

Study contacts

Dr. Rija Zainab, MS General surgery
principal investigator · Shaikh Zayed Hospital, Lahore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion